glp 1 drugs injection Understanding GLP-1 medications New Guidelines on GLP-1 Drugs
Description
If approved, Wegovy will be the first GLP-1 agent to treat MASH
The oral segment is expected to grow rapidly with CAGR of 22.9% during the forecast period due to its convenience and noninvasive administration, which improves patient observation
GIP (Glucose-dependent insulinotropic peptide): Enhances the secretion of insulin when blood sugar levels rise, further aiding in blood glucose control
Retatrutide Pending Approval - A triple-action injectable drug targeting GLP-1, GIP, and glucagon receptors
Legend: * Injection site nodule
Ishoy, P
